Andrew Calabrese

Proposing advancement criteria for efficient DMPK triage of new chemical entities.

A. Kulkarni, J. Riggs, C. Phan, 2014, Future medicinal chemistry.

Lead Diversification 2: application to P38, gMTP and lead compounds.

M. Bunnage, M. Bazin, T. Peakman, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans.

Steven W. Martin, A. Brown, D. Fradet, 2010, Journal of medicinal chemistry.

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.

L. LeBrun, Dan Zhu, B. Pagarigan, 2017, Journal of medicinal chemistry.

Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist.

A. Brown, W. Klute, Andrew Calabrese, 2009, Bioorganic & medicinal chemistry letters.

Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.

A. Brown, Andrew Calabrese, L. Watson, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans.

D. Fradet, M. Lansdell, D. Hepworth, 2010, Journal of medicinal chemistry.